1h Free Analyst Time
The publisher has been monitoring the diabetic neuropathy drugs market and it is poised to grow by $2.37 bn during 2021-2025, progressing at a CAGR of 12.20% during the forecast period. The report on the diabetic neuropathy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of diabetic neuropathy and new drug approvals and strong drug pipeline.
The diabetic neuropathy drugs market analysis includes the product segment and geographic landscape.
The diabetic neuropathy drugs market is segmented as below:
By Product
- Calcium channel alpha-2-delta ligand
- SNRIs and TCAs
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the rising awareness about diabetic neuropathy as one of the prime reasons driving the diabetic neuropathy drugs market growth during the next few years.
The report on diabetic neuropathy drugs market covers the following areas:
- Diabetic neuropathy drugs market sizing
- Diabetic neuropathy drugs market forecast
- Diabetic neuropathy drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diabetic neuropathy drugs market vendors that include Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. Also, the diabetic neuropathy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Five Forces Summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025
- SNRIs and TCAs - Market size and forecast 2020-2025
- Market opportunity by Product
Customer landscape
- Overview
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
Drivers, Challenges, and Trends
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
- Competitive landscape
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Alnylam Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- Grunenthal GmbH
- Johnson and Johnson Inc.
- NeuroBo Pharmaceuticals Inc.
- Novartis AG
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research Methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Product - Market share 2020-2025 (%)
- Comparison by Product
- Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025 ($ million)
- Calcium channel alpha-2-delta ligand - Year-over-year growth 2020-2025 (%)
- SNRIs and TCAs - Market size and forecast 2020-2025 ($ million)
- SNRIs and TCAs - Year-over-year growth 2020-2025 (%)
- Others - Market size and forecast 2020-2025 ($ million)
- Others - Year-over-year growth 2020-2025 (%)
- Market opportunity by Product
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Alnylam Pharmaceuticals Inc. - Overview
- Alnylam Pharmaceuticals Inc. - Product and service
- Alnylam Pharmaceuticals Inc. - Key offerings
- Alnylam Pharmaceuticals Inc. - Key customers
- Alnylam Pharmaceuticals Inc. - Segment focus
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product and service
- Astellas Pharma Inc. - Key offerings
- Astellas Pharma Inc. - Key customers
- Astellas Pharma Inc. - Segment focus
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Key customers
- Daiichi Sankyo Co. Ltd. - Segment focus
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Business segments
- Eli Lilly and Co. - Key offerings
- Eli Lilly and Co. - Key customers
- Eli Lilly and Co. - Segment focus
- Grunenthal GmbH - Overview
- Grunenthal GmbH - Product and service
- Grunenthal GmbH - Key offerings
- Grunenthal GmbH - Key customers
- Grunenthal GmbH - Segment focus
- Johnson and Johnson Inc. - Overview
- Johnson and Johnson Inc. - Business segments
- Johnson and Johnson Inc. - Key offerings
- Johnson and Johnson Inc. - Key customers
- Johnson and Johnson Inc. - Segment focus
- NeuroBo Pharmaceuticals Inc. - Overview
- NeuroBo Pharmaceuticals Inc. - Product and service
- NeuroBo Pharmaceuticals Inc. - Key offerings
- NeuroBo Pharmaceuticals Inc. - Key customers
- NeuroBo Pharmaceuticals Inc. - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global diabetic neuropathy drugs market: Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rising awareness about diabetic neuropathy.'
According to the report, one of the major drivers for this market is the increasing prevalence of diabetic neuropathy.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- Grunenthal GmbH
- Johnson and Johnson Inc.
- NeuroBo Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
